Avidity Biosciences, Inc. (NasdaqGM: RNAM)
Health Care · Biotechnology · US
$—
— today · — 1Y
Avidity Biosciences, Inc. (NasdaqGM: RNAM) operates in the Biotechnology industry within the Health Care sector.
trading between 35.70 and 73.06.
Tweenvest scores Avidity Biosciences, Inc. across four factors: quality 30/100, value 54/100, growth 100/100. Its strongest factor is growth.
RNAM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $18.75M
- P/E
- —
- EPS
- -4.97
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $73.06
- 52-week low
- $35.70
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 511
- Next earnings
- —
About Avidity Biosciences, Inc.
Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
- Founded
- 2012
- Listed since
- Jun 12, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.